HIV Vaccine Study: Comparing Intradermal and Intramuscular Administration
Author Information
Author(s): Launay Odile, Durier Christine, Desaint Corinne, Silbermann Benjamin, Jackson Angela, Pialoux Gilles, Bonnet Bénédicte, Poizot-Martin Isabelle, Gonzalez-Canali Gustavo, Cuzin Lise, Figuereido Suzanne, Surenaud Mathieu, Hamouda Nadine Ben, Gahery Hanne, Choppin Jeannine, Salmon Dominique, Guérin Corinne, Villada Isabelle Bourgault, Guillet Jean-Gérard
Primary Institution: Université Paris Descartes, Faculté de Médecine, Paris, France
Hypothesis
Does intradermal administration of an HIV vaccine induce similar immune responses compared to intramuscular administration?
Conclusion
Intradermal administration of the HIV vaccine was well tolerated and induced similar immune responses as the intramuscular route while using a smaller dose.
Supporting Evidence
- No severe adverse events were reported during the study.
- Local pain was significantly more frequent after intramuscular injection.
- Induced CD8+ T-cell responses were similar between both administration routes.
- Immunization route influenced the type of T-cells induced.
Takeaway
This study tested a new way to give an HIV vaccine by injecting it into the skin instead of the muscle, and it worked just as well with less medicine.
Methodology
A randomized, open-label trial with 68 healthy volunteers receiving either intradermal or intramuscular injections of the HIV vaccine over 24 weeks.
Potential Biases
Potential bias in self-reported adverse events and the open-label design.
Limitations
The study was not powered to demonstrate non-inferiority of the intradermal route compared to the intramuscular route.
Participant Demographics
Participants were healthy, HIV-uninfected adults aged 21 to 55, with a mix of males and females.
Statistical Information
P-Value
0.12
Confidence Interval
95% CI for adverse events
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website